{
    "2020-05-30": [
        [
            {
                "time": "2018-03-15",
                "original_text": "Eli Lilly and Company (LLY) Doesn’t Excite Hedge Funds",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "Hedge Funds",
                        "LLY"
                    ],
                    "sentiment_score": -0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2019-07-22",
                "original_text": "Drugs standards group nixes plan to kick pharma's crab blood habit",
                "features": {
                    "keywords": [
                        "Drugs standards",
                        "pharma",
                        "crab blood"
                    ],
                    "sentiment_score": 0.2,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2020-05-15",
                "original_text": "Lilly's CYRAMZA® (ramucirumab) Receives FDA Approval as First-Line Treatment for Metastatic EGFR-Mutated Non-Small Cell Lung Cancer",
                "features": {
                    "keywords": [
                        "CYRAMZA",
                        "FDA Approval",
                        "Non-Small Cell Lung Cancer"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "oncology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}